Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events

Table 1 Preferred reporting items for systematic reviews and meta-analyses checklist 2009[26]

Item	Topic	Reported on page
Title
1	Title includes systematic review or meta-analysis or both	97
Abstract
2	Structured abstract/summary background, objectives, data sources, eligibility criteria, participant, interventions, appraisal and synthesis methods, results, limitation, conclusions and implication of key findings, systematic review registration number	97
Introduction
3	Rationale for review, what is already known	98
4	Objectives: Specific questions addressed: (PICOS)-participants, interventions, comparisons, outcomes, study design	99
Methods
5	If review protocol (location and accessed URL, registration number)	NA
6	Eligibility criteria (study characteristics (PICOS, follow-up, etc.) and report characteristics (years searched, language, publication status), provide rationale	99
7	Information sources (databases with dates of coverage, contact with study authors to identify additional studies, date last searched)	99
8	Search strategy: Full search strategy for at least one database, including any limits used, such that it could be repeated	99
9	Study selection: (process for screening, eligibility)	99
10	Data collection process: Method of data extraction (piloted forms, independently, in duplicate) and any processes of obtaining and confirming data from investigators)	99
11	Data items: List and define all variables sought (e.g., PICOS, funding sources, etc.) and any assumptions	99-102
12	Risk of bias in individual studies: (Describe methods used for assessing risk of bias (at study or outcome level), how this info is to be used in any data synthesis)	102
13	Summary Measures: State principal summary outcome measures (RR or Difference in means) for pooled estimates of risk	103
14	Synthesis of results: Describe method of handling data and pooling data (measures of consistency with I2 for each meta-analysis)	103
15	Risk for bias across studies: (publication bias)	103
16	Additional analysis: Any subgroup or sensitivity analysis, meta-regression and if pre-specified	103
Results
17	Study selection: N of RCT screened, # assessed for eligibility, reasons for exclusions, with flow diagram	103-104, Figure 2
18	Study characteristics (for each study: study size, PICOS, follow-up with citations)	Table 4
19	Risk of bias within studies: Data on risk for bias and if there, any outcome level assessment (see #12, study quality)	107
20	Results of individual studies: Simple summary data for txt arm, effect estimates and confidence intervals for each study, with forest plot	Figures 3-5 Tables 4, 5
21	Synthesis of results: Data on each meta-analysis, pooled data, 95%CI and measures of consistency	Figures 3-5
22	Risk of bias across studies: results of any assessment of risk across studies (see #15)	Figures 6-8
23	Additional analysis data: if done (see #16, sub-groups)	107
Discussion
24	Summary of evidence: Summarize main findings, strength of evidence for each main outcome. Relevance to key groups (providers, users, policy makers)	110
25	Limitations: Limitations at study level and outcome level (risk of bias), at review-level (incomplete retrieval of identified research, reporting bias)	113
26	Conclusions: General interpretation of results compared to other evidence, implications for future research.	113
Funding
27	Funding: describe funding sources	Not found

The PRISMA Statement. Available from: URL: http://prisma-statement.org/statement.htm. Accessed 7/25/2014.